<DOC>
	<DOCNO>NCT02153502</DOCNO>
	<brief_summary>The objective 10-week study evaluate efficacy , safety , tolerability AVP 786 adjunctive therapy compare placebo patient major depressive disorder ( MDD ) show inadequate response standard antidepressant treatment . A secondary objective study ass pharmacokinetics ( PK ) AVP-786 potential correlation pharmacodynamic effect .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Study AVP-786 Adjunctive Therapy Patients With Major Depressive Disorder With Inadequate Response Antidepressant Treatment</brief_title>
	<detailed_description>It estimate approximately 200 patient participate study approximately 30 enrol center US . Eligible patient study must MDD define Diagnostic Statistical Manual Mental Disorders ( DSM-IV-TR ) criterion , show inadequate response standard antidepressant treatment . This multicenter , randomize , double-blind , placebo-controlled , study 10 week duration . Following screening procedure assessment inclusion exclusion criterion , eligible patient randomize study . Study medication administer orally BID ( 1 capsule morning 1 capsule evening , approximately 12 hour apart ) throughout treatment period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Clinical diagnosis major depressive episode ≤ 24 month duration HAMD17 score ≥ 20 . Documented significant ( 25 % great ) change QIDSSR16 score Screening Baseline visit . Patients deem inadequate response ( le 50 % symptom reduction ) least 1 3 adequate antidepressant trial current depressive episode . Patients must receive ongoing treatment adequate dose antidepressant . Body Mass Index ( BMI ) 1835 kg/m² . History myasthenia gravis . Have cardiovascular concern : History complete heart block , QT interval correct heart rate ( QTc ) prolongation , torsades de pointes . QTc use Fridericia 's formula ( QTcF ) screen &gt; 450 msec male &gt; 470 msec female base central review screen visit , unless due ventricular pacing . Any family history congenital QT interval prolongation syndrome . Known hypersensitivity/intolerance DM , Q , opiate drug ( codeine , etc . ) , ingredient study medication . Pose current suicide risk , evidence following : It judgment investigator subject may risk suicide . The subject rat `` yes '' question 4 question 5 Baseline CSSRS , recent episode occur within past 12 month . The subject attempt suicide within past 6 month Presence current DSMIVTR Axis I disorder exception : generalize anxiety disorder ( GAD : 300.02 ) , social anxiety disorder ( 300.23 ) , dysthymic disorder ( 300.4 ) , specific phobia ( 300.29 ) . Patients comorbid GAD , social anxiety disorder , specific phobia ineligible comorbid condition clinically unstable , primary focus treatment within 6 month period prior screen Axis I diagnosis : Delirium , dementia , amnestic , cognitive disorder ; Schizophrenia psychotic disorder , base M.I.N.I . ; Bipolar I II disorder , base M.I.N.I . Clinically significant Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>